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Towards ‘‘bionic’’ proteins: replacement of
continuous sequences from HIF-1a with
proteomimetics to create functional p300 binding
HIF-1a mimics†
George M. Burslem,‡ab Hannah F. Kyle,bc Alexander L. Breeze,bcd
Thomas A. Edwards,bc Adam Nelson,ab Stuart L. Warrinerab and Andrew J. Wilson*ab
Using the HIF-1a transcription factor as a model, this manuscript
illustrates how an extended sequence of a-amino acids in a poly-
peptide can be replaced with a non-natural topographical mimic of
an a-helix comprised from an aromatic oligoamide. The resultant
hybrid is capable of reproducing the molecular recognition profile
of the p300 binding sequence of HIF-1a from which it is derived.
Nature uses a stunning array of architectures to carry out complex
tasks including catalysis and cell signalling. Biopolymers are able
to perform these feats because they self-organise and present
functional motifs (e.g. an active site or binding surface) through
precise 3-D orientation of primary structure. A long term goal in
chemical and synthetic biology, therefore, is to expand on this
diversity, and through the incorporation of non-natural function-
ality, elaborate bio-macromolecules with enhanced or orthogonal
functionality and/or properties.1 Foldamers are oligomers that
adopt well-defined conformations and either replicate structural
and functional features of natural biomacromolecules or access,
using non-natural building blocks, novel folds and functions not
found in nature. An alternative approach to this bottom-up
strategy, termed ‘‘protein-prosthesis’’, lies at the cross-roads
with strategies to chemically2–4 or genetically5 introduce non-
natural function into proteins. In protein prosthesis,6,7 backbone
engineering8 allows individual residues or sequences within
proteins to be replaced with non-natural residues.9–13 Notable
examples include the incorporation of b-amino acid residues in the
B1 domain of Streptococcal protein G (GB1)14 and Betabellin-14,15
the re-engineering of a heterodimeric chorismate mutase enzyme16
using sequence based design, the replacement of loop regions in
GB1 using PEG17 and the incorporation of an entire b-amino acid
topological mimic of an a-helix into IL8.18 a-Helix mimetics19–23
employ a suitably functionalised generic scaffold to reproduce the
spatial projection and composition of key side chains found at a
helical interface between two proteins. Such a-helix mimetics have
been shown by us24,25 and others26–28 to act as potent inhibitors of
protein–protein interactions, but there are limited studies on their
incorporation into higher-order structures.29 In this manuscript we
illustrate the first steps towards this goal by replacement of an
entire segment of the HIF-1a transactivation domain with an
aromatic oligoamide (Fig. 1). In doing so, we provide the first
example of a replacement of an extended peptide sequence with a
topographical mimic.
Our design focused upon a minimal region of the HIF-1a
C-terminal transactivation domain (C-TAD) which interacts with
the CREB-binding protein (CBP)/p300 co-activator to promote
transcription (Fig. 1a).30,31 Previously our group illustrated that
two helical domains (HIF-1a794–826, i.e. helix 2/3) within the
42 residue C-TAD peptide (HIF-1a782–826) were necessary for
measurable binding to p300 (Fig. 1c).32 We had also identified a
helix mimetic 1 based on our 3-O-alkylated aromatic oligo-
amide scaffold which was designed to mimic helix 3 of the
HIF-1a C-TAD (HIF-1a816–826) and shown to act as a low mM
(IC50 = 9.2  0.9 mM) inhibitor of the HIF-1a/p300 interaction
(Fig. 1b).33 In our design (hybrid 2), the helix 3 region (HIF-1a816–826)
of HIF-1a (HIF-1a782–826) was replaced with the previously identified
helix mimetic33 and the remainder of the sequence preserved
(Scheme 1a). In parallel, we also designed a series of helix 2/3
conjugates 3a–c linked by PEG spacers (Scheme 1a); the purpose in
designing these compounds was to ascertain the extent to which the
p300 binding potency might be maintained when the linker region
between key helical regions (HIF-1a794–808 and HIF-1a816–826)
was replaced.
Previously developed solid-phase synthesis methods for the
preparation of oligobenzamides facilitate rapid preparation of
helix mimetic trimers34 but we found the method unsuitable
for preparation of the target peptide-helix mimetic conjugate 2.
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To address the poor nucleophilicity of trimeric oligoamides with
a terminal aniline, Fmoc-glycine was coupled to an isobutyl
monomer 7 using dichlorotriphenylphosphorane (Scheme 1b).
Noteworthy in this sequence was the use of an allyl ester, which
facilitated ester cleavage in the presence of the base-labile Fmoc
protecting group. Fischer esterification of nitro acid 4 with allyl
alcohol gave ester 5 followed by alkylation with isobutyl bromide
to give alkoxy nitro ester 6. The aryl nitro group was reduced to
the aniline 7 using stannous chloride then acylated with Fmoc-
glycine via in situ acid chloride formation with dichlorotriphenyl-
phosphorane. Finally the acid was revealed with palladium(0)
tetrakis triphenylphosphine and sodium toluenesulfinate
scavenger35 to give the final building block 8 in good yield.
The desired peptide-helix mimetic hybrid 2 was subsequently
obtained using Fmoc based solid-phase synthesis (Scheme 1c).
O-Alkylated 2-hydroxybenzoic acid monomers were assembled
on resin using the previously described microwave assisted
approach until Fmoc-Gly-iBu dipeptide building block 8 had
been coupled. Following deprotection, the oligomer was then
extended using conventional Fmoc solid phase synthesis with
HCTU-mediated couplings. The preparation of hybrid 2 was
performed in a single run on an automated peptide synthesiser
(CEM Liberty) followed by HPLC purification (see ESI† for
additional details). PEG linked helix 2/3 conjugates 3a–c were all
synthesized using conventional Fmoc based solid phase synthesis
and labelled with fluorescein to permit direct binding analyses
(Scheme S2a, see ESI,† for details of the synthesis).
The hybrids 2 and 3a–c were then tested in a previously
described fluorescence anisotropy p300/HIF-1a competition
and p300 binding assays respectively (Fig. 2a).33 Hybrid 2 was
shown to inhibit the interaction with comparable affinity to the
HIF-1a794–826 peptide from which it was derived (IC50 values
hybrid 2 = 83  1.8 mM; HIF-1a794–826 = 89  2.8 mM).32
Crucially, to avoid disulfide formation, the helix mimetic peptide
2 conjugate bears a cysteine to serine modification (underlined
in Scheme 1), whereas the peptide does not. The mutation of this
cysteine residue to a serine has been shown to reduce affinity by
approximately 10-fold for the native sequence,36 which should be
considered when comparing the affinities. It should also be
noted that this affinity does not derive solely from the peptidic
region, as a peptide comprising the same residues (HIF-1a794–815)
shows no inhibitory activity (IC50 4 500 mM).
32
The PEG linked hybrids 3a–c exhibited lower affinity for
p300 – Kd 3c = 144(13) mM, 3a/b 4 200 mM (Fig. 2c) – than
FITC-HIF-1a794–826 (Kd = 6.74  0.54 mM).32 This suggests either
that the linker is not sufficiently long or that the side chains
from the linker between helices 2 and 3 make productive non-
covalent contacts with p300. A requirement for optimal linker
length is supported by the fact that as the length of the PEG
linker in 3a–c increases, so does binding affinity. In spite of the
weaker binding affinities observed for 3a–c, the weak binding
for HIF794–804 (helix 2) and HIF816–826 (helix 3) in isolation
and lack of allosteric co-operativity between the two observed
previously,32 indicates chelate co-operativity for 3a–c here and
validates the approach.
At first the lower inhibitory potency of both HIF-1a794–826
and hybrid 2 in comparison to helix mimetic 1 (9.2(0.9) mM)
which we determined previously,33 might seem counterintuitive.
One explanation that might account for this observation is that
there may be a non-specific component to PPI inhibition asso-
ciated with the aromatic oligoamide helix mimetic 1 (supported in
part by a non-unity Hill co-efficient for the curve fitting, a property
not observed for 2). Indeed, more hydrophobic compounds fre-
quently bind with greater potency but poorer specificity and
selectivity,37 whilst even for peptides, truncation can similarly lead
tomore potent but less specific binding.38 We therefore performed
further biophysical analysis. Although we illustrated previously
that inhibition of HIF-1a/p300 by 1 was specific to the scaffold and
selective in comparison to the eIF4E/4G interaction,33 we expanded
the range of assays here. Compound 1 exhibited inhibition of the
p53/hDM2 interaction (IC50 = 16.4  1.0 mM) when assessed in a
fluorescence anisotropy competition assay (Fig. 3). In contrast,
hybrid 2 was shown to exhibit minimal inhibition of this inter-
action (p53/hDM2 IC50 4 100 mM). Thus, by adding native amino
Fig. 1 Approach for assembly of a ‘‘bionic’’ protein (a) NMR structure
of the HIF-1a C-TAD in complex with p300; PDB ID: 18LC (p300 in green,
helix 1 of HIF-1a in blue, key binding sequence comprising helices 2 and 3
of HIF-1a in purple and zinc as grey spheres), (b) structure of a proteomi-
metic inhibitor of HIF-1a/p300 based on helix 3 of HIF-1a (i, i + 4 and i + 7
mimicking side chains coloured red, green and blue respectively) (c) sche-
matic depicting prior truncation studies on HIF-1a C-TAD together with
conceptual structure of hybrids comprising peptide and proteomimetic or
non-natural linkers.
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acid residues from the HIF-1a sequence to the core helix
mimetic 1 in hybrid 2, the specificity and selectivity of binding
towards target interactions was improved.
In conclusion, we have described the first example of a
peptide-helix mimetic hybrid and in doing so conceptually
illustrated that extended sequences from proteins can be
replaced with molecules that topographically mimic such
sequences. Our immediate eﬀorts will focus on structural and
biophysical studies on these hybrid mimetics with a view to
optimizing the binding properties. Future eﬀorts will focus on
incorporating such secondary structure mimetics into longer
protein sequences and exploring this replacement strategy for a
broader array of protein functions. Application of this generic
approach for preparation of functional peptide-helix mimetic
hybrids, could allow assembly of protein-like objects with enhanced
properties e.g. proteolytic and thermal stability, married with
Scheme 1 (a) Structure of peptide-helix mimetic hybrid 2 and 3a–3c (PEG = polyethylene glycol), (b) synthetic route for assembly of the key N-terminal
Fmoc glycyl 3-butyloxy-4-aminobenzoic acid building block 8 (c) outline of approach used to synthesise hybrid 2.
Fig. 2 Biophysical screening of HIF-1a peptides and hybrids, HIF-1a794–826,
2 and 3a–c (a) fluorescence anisotropy (FA) competition data for inhibition
of p300/FITC-HIF-1aC-TAD for HIF-1a794–826 and 2 (b) (FA) binding data for
3a–c to p300 (schematic structure shown below).
Fig. 3 Biophysical screening of helix mimetic 1 and hybrid 2 to profile
selectivity; FA competition data for inhibition of p53/hDM2.
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superior recognition properties (e.g. selectivity) when compared
with simpler proteomimetics.
We thank AstraZeneca and EPSRC for PhD studentships
(G. M. B. and H. F. K.) and the European Research Council
[ERC-StG-240324, and ERC-PoC 632207] for support.
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